Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
2 more messages on ACB discussion group today saying their Trusts are anticipating demand following NICE approval and preparing for this. My confidence has waxed and waned with this share but right now it has never been stronger. EU business development manager being recruited as well - you sell if you want to but this man is not for selling!
Someone is buying at a great price
News of this is hitting multiple NHS Trusts. A subscription website I am on has had two of the largest Trusts in UK (Not Manchester) commenting that they are getting queries from clinicians. POCT staff are a little resistant as it means more work for them but clinician demand will determine the outcome - looking more positive than it has for a long time.
It is very common in NHS procurement for testing equipment to do a reagent rental agreement where there are no upfront costs and the capital is loaded into reagents and consumables over a 3/5/7 year term. Actually better for the supplier over the long term and means the NHS doesn't need a high capital investment.
I see all the posts saying DB should go - and be replaced by who? He is very experience in diagnostics, Bayer, Siemens, Leica etc he understands NHS contracts and tenders so why would you want to replace him? Getting a start-up to market is incredibly challenging in any country and doing so in the NHS is without doubt the worst.
He has a seemingly good product that needs to get through various regulatory approvals - not guaranteed ever but if he does and the tech is good it will sell.
I do wonder why some people invest in AIM stock - high risk with occasional high return.
Before the "he couldn't sell Covid in a pandemic" arguments come - neither could many other companies. Covid quickly became a commodity market and dominated by the big players - Abbott ID Now taking swathes of the market globally.
Illumina sequencing is so far away from what GDR are doing even putting it here is a joke. Whole genome sequencing is super clever and will uncover some rare diseases but GDR are targeting just one very specific genetic code that has a huge clinical benefit. All that is needed is acceptance and adoption and of course sales!
I do wonder most days why I got into this share...... just when you see light darkness follows
The NHS is a cumbersome machine. Mostly procurement takes the form of tenders which can drag on for a year or more. DB getting NICE to do their evaluation has pulled a blinder - assuming the outcome is as expected.
Personally I am more than happy to sit on this and wait for results in the NHS, especially if more dynamic health services who are not restricted by tendering start to use the technology.
Outlook looks good from my perspective. Talk of every Trust in the country immediately adopting this was wishful thinking - nothing is quick in our NHS.
This has literally nothing to do with what GDR are doing. This is about genome sequencing and completely irrelevant herehttps://www.england.nhs.uk/genomics/nhs-genomic-med-service/
The CEO is currently enjoying some sunshine in Vegas. True story
Great to see a rise but a long way to go before most investors are going to get close to break even (me included) Distribution agreements are a positive sign but sales numbers are what will make this truly recover to a reasonable level.
This is without doubt the worst share I have invested in (others have been poor but this....) No option now other than park it and hope they recover a bit over the long haul. So much potential but I guess this is AIM for you!